As in many other cancers, EGFR plays a prominent role in promoting growth of CRC [24], [25]; biological therapies targeting EGFR are FDA-approved for treatment of EGFR-positive advanced CRC [26], [27]. The gene discussed is EGFR; the disease is colorectal carcinoma.